CCCZ integrates and supports all cancer research activities of the UZH, USZ, Balgrist University Hospital and the University Children's Hospital Zurich.
Dedicated research areas have been established for Tumor Immunology, (Epi)Genetics & Genomics, Oncogenic Signaling and Imaging, Technology Development and Digitalization. In these areas, scientists and physicians from more than 60 research groups and clinical departments work closely together to facilitate the translation of scientific discoveries into clinical application. The overall aim is to integrate basic research into translational and clinical concepts towards precision oncology.
Research studies show that the immune system can influence the development and progression of cancer. The use and manipulation of the immune system is therefore a promising therapeutic option to fight cancer. Physicians and scientists of the CCCZ Research Area Tumor Immunology investigate the interaction between the tumor and immune system. The overall aim is to develop novel immunotherapies with minimal side effects.
Many of the characteristics of cancer cells, such as malignant growth and the ability to metastasize, are influenced by (epi)genetic and genomic changes. Research groups of the CCCZ Epigenetics, Genetics and Genomics Research Area study various aspects of gene alterations in cancer aiming to develop targeted treatment concepts.
Signal transduction pathways within and between cells are often deregulated in cancer and contribute to uncontrolled growth and metastasis. In the CCCZ Research Area Oncogenic Signaling, scientists and physician investigate the effect of cancer drugs at the molecular level. Another focus of the program is to overcome drug resistance of cancer cells.
The CCCZ Research Area for Imaging, Technology Development and Digitization pursues the goal of developing personalized diagnosis and treatment methods for cancer. Novel imaging techniques such as innovative MRI sequences and PET imaging as well as radiomics enable more precise characterization of cancer. High-throughput molecular methods like sequencing, proteomics, metabolomics and imaging are essential for molecular diagnostics and monitoring of disease progression. For the analysis of scientific and clinical data, the development of modern bioinformatics and information technologies are of central importance.